Nepsis Inc. Sells 2,008,271 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Nepsis Inc. reduced its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 95.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 96,257 shares of the company’s stock after selling 2,008,271 shares during the quarter. Health Catalyst comprises approximately 0.1% of Nepsis Inc.’s holdings, making the stock its 26th largest holding. Nepsis Inc.’s holdings in Health Catalyst were worth $681,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Millennium Management LLC lifted its position in Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after buying an additional 1,184,131 shares during the last quarter. Fred Alger Management LLC purchased a new stake in shares of Health Catalyst in the third quarter valued at $6,858,000. Portolan Capital Management LLC bought a new stake in shares of Health Catalyst in the 3rd quarter worth about $5,402,000. Impax Asset Management Group plc boosted its stake in shares of Health Catalyst by 16.4% during the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after purchasing an additional 360,201 shares during the period. Finally, Essex Investment Management Co. LLC bought a new position in Health Catalyst during the 3rd quarter valued at about $2,012,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Health Catalyst news, CFO Jason Alger sold 19,599 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $163,063.68. Following the sale, the chief financial officer now owns 86,712 shares of the company’s stock, valued at $721,443.84. The trade was a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total value of $40,109.30. Following the completion of the sale, the chief operating officer now directly owns 129,690 shares of the company’s stock, valued at $998,613. The trade was a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 81,169 shares of company stock worth $639,174. Company insiders own 2.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on HCAT shares. Royal Bank of Canada decreased their price objective on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 15th. Wells Fargo & Company dropped their price objective on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday. Citigroup cut their price objective on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Health Catalyst currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.91.

Health Catalyst Stock Performance

Shares of HCAT opened at $5.77 on Friday. Health Catalyst, Inc. has a 52-week low of $5.35 and a 52-week high of $10.99. The firm’s fifty day moving average is $7.34 and its two-hundred day moving average is $7.50. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. Health Catalyst’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.22) EPS. Equities analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.